Isomorphic Labs Completes $5 Billion Series C Funding
Isomorphic Labs, a UK-based AI drug discovery company founded by Demis Hassabis, announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest heavily. Together with its previous $600 million first external funding and $2.1 billion Series B, the company's publicly disclosed funding totals $7.7 billion. The new funds will be used to upgrade its drug design engine IsoDDE, expand its in-house and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure.
Why read this
AI score 62
Beyond the funding size and the list of investors, the original text also explains the shift in how the funds will be used, from model research and development to drug pipelines and clinical infrastructure.
Topics
Body · AI translation
Zhidx November 17 news: Just now, Isomorphic Labs, the UK-based AI drug discovery company founded by Nobel laureate and Google DeepMind co-founder Demis Hassabis, announced the completion of a $5 billion (approximately RMB 33.3 billion) Series C funding round, which was oversubscribed.
▲Hassabis announces that Isomorphic Labs has completed its Series C funding round (Image source: X)
In March 2025, Isomorphic Labs announced the completion of a $600 million (approximately RMB 4 billion) first external funding round. In May of this year, the company secured a further $2.1 billion (approximately RMB 14 billion) Series B round, setting a new record at the time for a single funding round in the global AI pharmaceutical industry. Including this Series C round, the total publicly disclosed funding for Isomorphic Labs amounts to $7.7 billion (approximately RMB 51.3 billion).
This round was co-led by Greenoaks and Sequoia Capital, with participation from a16z and several new investors, while Alphabet continued to invest heavily. All existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, also participated in this round.
Isomorphic Labs was founded in 2021 and is headquartered in London, UK, focusing on using AI to design and develop new drugs. The company plans to use the new funds to upgrade its proprietary drug design engine IsoDDE, expand its internal and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure. The company says its internal oncology and immunology programs and partnered programs have achieved positive preclinical results and are preparing to enter clinical trials.
Isomorphic Labs was incubated and founded by Google DeepMind and is an AI drug discovery company under Alphabet, Google's parent company, operating as an independent entity that raises external funding. The company is led by founder and CEO Demis Hassabis and President Max Jaderberg.
Hassabis is a co-founder of Google DeepMind, chairman of Google DeepMind and chief scientist of Alphabet, and was awarded the 2024 Nobel Prize in Chemistry for his research on AlphaFold in protein structure prediction.
▲Isomorphic Labs founder and CEO Hassabis
Jaderberg holds a doctorate from the University of Oxford and previously led DeepMind's open-ended learning research team. He is a founding team member of Isomorphic Labs, previously served as chief AI officer, led the development of the company's drug design engine and models such as AlphaFold 3, and became the company's president in January 2026.
Hassabis said that when Isomorphic Labs was founded, the team believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process.
He also said that Isomorphic Labs' drug design engine is generating molecules with greater precision and speed, and that this funding round will help the team advance its work faster: building foundational biology models, deepening understanding of systemic disease mechanisms, and advancing the first therapeutic programs toward clinical trials.
Isomorphic Labs' core technology is its proprietary drug design engine IsoDDE. The engine integrates a suite of foundational simulation AI models that can cover multiple therapeutic areas and different drug modalities.
IsoDDE can explore vast chemical space and help R&D teams design, optimize and screen molecules with desirable drug-like properties. Isomorphic Labs says these simulation models are pushing predictions close to experimental accuracy, providing more capabilities for innovative drug discovery.
In addition to simulation models, Isomorphic Labs has also developed proprietary agents for exploring and reasoning about complex biological systems. The company says that combining its models and agents has continued to drive progress across multiple types of drug candidate pipelines. At present, the company's internal oncology and immunology programs and partnered programs have achieved positive preclinical results, laying the foundation for entering the clinical stage.
Isomorphic Labs President Jaderberg said the team is able to achieve reproducible scientific progress every week with the help of its models and translate that into better molecular properties, and these molecules have the potential to be further developed into new drugs. The company's interdisciplinary team brings together machine learning researchers and drug discovery researchers, and is trying to solve complex biological problems that have been stalled for decades.
After this funding round, Isomorphic Labs will continue to refine IsoDDE and use more advanced models to explore new areas of biology.
The company also plans to build a partner ecosystem and deepen its understanding of disease mechanisms to support the development of new classes of therapeutic drugs. At the same time, Isomorphic Labs will build global bioengineering infrastructure and a scalable, AI-centered translational research and clinical development system to support drug candidates entering clinical trials.
The use of this funding has expanded from model research and development to drug pipelines, translational research and clinical development infrastructure. For Isomorphic Labs, how to translate computational prediction and molecular design capabilities into drug candidates that can enter clinical trials is an important task for the next stage.
At present, most of Isomorphic Labs' main achievements are still at the preclinical stage. As the first batch of programs advances toward clinical trials, the safety, efficacy and development progress of its drug candidates will become important criteria for testing AI drug design capabilities.
Source: Isomorphic Labs, X
This article comes from the WeChat public account "Zhidongxi", author: Yang Jingli, editor: Li Shuiqing, published with authorization from 36Kr.
AI Trends